Neurochemical Profile of the Antidepressant Moclobemide, a Reversible Type A Monoamine Oxidase Inhibitor with Minimal Tyramine Potentiating Activity in Rats

  • W. P. Burkard
  • R. Kettler
  • M. Da Prada
  • W. E. Haefely


Moclobemide [p-chloro-N-(2-morpholinoethyl)-benzamide HCl; Ro 11-1163] is a short-acting, reversible, preferential type A monoamine oxidase inhibitor (MAOI).1,2 This benzamide derivative is nontoxic and chemically unrelated to any of the irreversible MAOIs of the first generation. Accordingly, in contrast to iproniazid, moclobemide did not show hepatotoxic effects in rats.3


Mean Arterial Blood Pressure Monoamine Oxidase Inhibitor Adenylate Cyclase System Neurochemical Profile Benzamide Derivative 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Da Prada M, Keller HH, Kettler R, et al. Ro 11-1163, a specific and short acting MAO inhibitor with antidepressant properties. In Kamijo K, Usdin E, Nagatsu T (eds): Monoamine Oxidase. Basic and Clinical Frontiers. Amsterdam: Excerpta Medica, 1981; 182.Google Scholar
  2. 2.
    Keller HH, Kettler R, Keller G, et al. Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and Ro 16-6491. Naunyn Schmiedebergs Arch Pharmacol 1987; 335: 12.PubMedCrossRefGoogle Scholar
  3. 3.
    Schläppi B. The lack of hepatotoxicity in the rat with the new and reversible MAO-A inhibitor moclobemide in contrast to iproniazid. Drug Res 1985; 35: 800.Google Scholar
  4. 4.
    Kan J-P, Steinberg R, Mouget-Goniot C, et al. SR95191, a selective inhibitor of type A monoamine oxidase with dopaminergic properties. II. Biochemical characterization of monoamine oxidase inhibition. J Pharmacol Exp Ther 1987; 240: 251.PubMedGoogle Scholar
  5. 5.
    Da Prada M, Kettler R, Burkard WP, et al. Moclobemide, an antidepressant with short-lasting MAO-A inhibition: brain catecholamines and tyramine pressor effects in rats. In Tipton KF, Dostert P, Strolin-Benedetti M (eds): Monoamine Oxidase and Disease. New York: Academic Press, 1984; 137.Google Scholar
  6. 6.
    Korn A, Da Prada M, Raffesberg W, et al. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol 1988; 11: 17.PubMedCrossRefGoogle Scholar
  7. 7.
    Sulser F, Janowsky AJ, Okada F, et al. Regulation of recognition and action function of the norepinephrine (NE) receptor-coupled adenylate cyclase system in brain: implication for the therapy of depression. Neuropharmacology 1983; 22: 425.PubMedCrossRefGoogle Scholar
  8. Stefanis CN. Personal communication, 1987.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1989

Authors and Affiliations

  • W. P. Burkard
  • R. Kettler
  • M. Da Prada
  • W. E. Haefely

There are no affiliations available

Personalised recommendations